Zobrazeno 1 - 10
of 395
pro vyhledávání: '"Michael A, Nauck"'
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Renal outcomes in patients with type 2 diabetes following treatment with sodium–glucose co-transporter-2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP1RAs) have not been directly compared. This study com
Externí odkaz:
https://doaj.org/article/4e85355979f1434fb1f87ffca4ddb65b
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-13 (2023)
Abstract Background Recent large clinical trials have demonstrated cardiovascular benefits of similar overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy in subject
Externí odkaz:
https://doaj.org/article/5ebce3dbe6a149abb45adc8064b2400e
Publikováno v:
Diabetes & Metabolism Journal, Vol 47, Iss 1, Pp 140-146 (2023)
In clinical practice, the distinction between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) can be challenging, leaving patients with “ambiguous” diabetes type. Insulin-treated patients (n=115) previously diagnosed with T2DM
Externí odkaz:
https://doaj.org/article/29e7a9aed8e04adcbfabb38109f34c39
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Cardiovascular outcomes trials (CVOTs) with novel drugs to treat type 2 diabetes have uniformly chosen the composite “major adverse cardiovascular events (MACE)” as their primary endpoint, but they also report hazard ratios for individua
Externí odkaz:
https://doaj.org/article/7f7efbf9353e4f0f80056a38b2d032c7
Autor:
Michael A. Nauck, David A. D‘Alessio
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-16 (2022)
Abstract Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators o
Externí odkaz:
https://doaj.org/article/6a27eeec00834f67888d5f48aa9020ba
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 11, Iss 4 (2023)
Basal insulin treatment for type 2 diabetes is usually initiated on a background of oral glucose-lowering medications (OGLM). We wanted to examine the influence of various OGLMs on fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) values achiev
Externí odkaz:
https://doaj.org/article/83743ec444b54d95ba0fbca19c1f614f
Autor:
Michael A. Nauck, Johannes W. Dietrich
Publikováno v:
The Lancet Regional Health. Europe, Vol 14, Iss , Pp 100318- (2022)
Externí odkaz:
https://doaj.org/article/98a3f31ea22e4c83a7ac796cfbd3dd11
Publikováno v:
Journal of Diabetes Research, Vol 2022 (2022)
Background/Aim. We aimed to examine beneficial and adverse outcomes of basal insulin titration performed with different fasting plasma glucose (FPG) titration targets (TT). Methods. A PubMed literature search retrieved 43 reported prospective clinica
Externí odkaz:
https://doaj.org/article/ee56b52064fd45c4831189273827d8c0
Publikováno v:
Nutrients, Vol 15, Iss 1, p 248 (2023)
The efficacy and safety of medications can be affected by alterations in gut microbiota in human beings. Among antidiabetic medications, incretin-based therapy such as dipeptidyl peptidase 4 inhibitors might affect gut microbiomes, which are related
Externí odkaz:
https://doaj.org/article/55641122b56740d283f4ed2bb46e9686
Autor:
Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, Timo E. Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D. Peterson, Harvey D. White, Russell Scott, Rury R. Holman
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-10 (2019)
Abstract Background To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Methods TECOS randomized 14,671 participants with type 2 diabet
Externí odkaz:
https://doaj.org/article/f1b3ffca4f5a46b0a09a054de2bd029d